Source - SMW
Molecular diagnostics group Yourgene Health said it had restructured its financial and commercial relationship with Life Technologies.

Life Technologies had exercised warrants at 9.2p per share, giving it a 9% stake in the company.

It had also agreed to write off a remaining £12.7m of loans, leaving the company substantially debt free.

The write off was subject to Yourgene paying a 'modest' commission on sales within Southeast Asia, up to a cap of £6.5m.

Chief executive Lyan Rees said the restructure placed the company in a stronger position to capitalise on 'the significant global non-invasive prenatal testing opportunity'.


At 9:48am: (LON:YGEN)  share price was +0.75p at 13.75p